Clinical Trial Update: Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating pembrolizumab plus blinatumomab for recurrent or refractory CD19-positive, Philadelphia chromosome-positive acute lymphobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: CD19 Positive, Philadelphia Chromosome Positive | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING